0001113481-11-000006.txt : 20110602 0001113481-11-000006.hdr.sgml : 20110602 20110602164931 ACCESSION NUMBER: 0001113481-11-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110526 ITEM INFORMATION: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20110602 DATE AS OF CHANGE: 20110602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINES CO /DE CENTRAL INDEX KEY: 0001113481 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043324394 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31191 FILM NUMBER: 11889081 BUSINESS ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-290-6000 MAIL ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: MEDICINES CO/ MA DATE OF NAME CHANGE: 20000504 8-K 1 form8-kannualmeeting.htm FORM 8-K Form 8-K 2011 annual meeting
 

    
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
____________
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 26, 2011
 
 
The Medicines Company
(Exact Name of Registrant as Specified in Charter)
 
 
Delaware
 
000-31191
 
04-3324394
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
                       
 
8 Sylvan Way
Parsippany, New Jersey
 
07054
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant's telephone number, including area code: (973) 290-6000
 
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
Item 5.05. Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
On May 26, 2011, the Board of Directors of The Medicines Company (the “Company”) approved a revised Code of Business Conduct and Ethics, now referred to as the Company's Global Code of Conduct and Ethics (the “Revised Code”), which applies to all directors and employees of the Company. The main reasons for revising the Company's Code of Business Conduct and Ethics was to expand its scope to address the global nature of the Company's operations, to better reflect the Company's corporate structure and to update content based upon changes in laws, rules and regulations within the jurisdictions in which the Company does business. The Code was revised to, among other things, (1) emphasize the applicable laws and the Company's guidelines governing interactions with government officials, health−care professionals, customers, suppliers, and other third parties; (2) enhance the description of the policies and regulations pertaining to anti-corruption; (3) clarify the Company's requirements for the handling of personal data and employee use of information technology; (4) clarify the Company's existing policies regarding research and development and patient safety ethics, record retention, and protection of the Company's intellectual property; and (5) change the contact information for anonymous and confidential submission of information from an internal contact point to a global external service provider. In addition, certain administrative and non−substantive revisions were made to the Revised Code.
The Revised Code is available on the corporate governance section of “Investor Relations” on the Company's website, www.themedicinescompany.com.
 
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the Company's Annual Meeting of Stockholders held on May 26, 2011 (the “Annual Meeting”), stockholders considered: (1) the election of three directors for terms expiring in 2014; (2) a proposal to approve, on an advisory basis, the Company's executive compensation; (3) a proposal to vote, on an advisory basis, on the frequency with which the Company's executive compensation will be subject to future advisory stockholder votes; and (4) the ratification of the appointment of Ernst & Young LLP as the Company's independent auditors for the current fiscal year.
 
The voting results at the Annual Meeting with respect to each of the matters described above, were as follows:
 
1.
The three directors were elected based upon the following votes:
 
For
Withheld
Broker Non-Votes
Robert J. Hugin
47,343,759
 
120,807
 
2,592,818
 
Clive A. Meanwell
46,926,925
 
537,641
 
2,592,818
 
Elizabeth H.S. Wyatt
47,315,846
 
148,720
 
2,592,818
 
 
 
2.
The Company's executive compensation was approved, on an advisory basis, based upon the following votes:
 
For
Against
Abstain
Broker Non-Votes
46,901,405
548,127
15,034
2,592,818

 
 

 
3.
The Company's stockholders voted, on an advisory basis, for the Company to hold advisory votes on its executive compensation on an annual basis based upon the following votes:
 
1 Year
2 Years
3 Years
Abstain
Broker Non-Votes
38,163,763
5,698,483
3,592,662
9,658
2,592,818
 
4.    The independent registered public accounting firm for the current fiscal year was ratified based upon the following votes:
 
For
Against
Abstain
49,776,146
269,768
11,470
 
 
 
 
        

 
 

 
 
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
THE MEDICINES COMPANY
Date:  June 2, 2011        
By:    /s/ Paul M. Antinori
Paul M. Antinori
Senior Vice President and General Counsel